A comparative bioavailability of reformulated ibuprofen 2% and 4% oral suspensions (Berlin Chemie AG) and reference ibuprofen (Nurofen®) 200 mg/5 ml oral suspension in healthy male and female adult subjects under fasting conditions: an open-label, randomized, single-dose, three-period, three-treatment, three-sequence crossover study
Phase 1
- Conditions
- In this study will be no subjects involved with any specific medical condition or diseaseTherapeutic area: Not possible to specify
- Registration Number
- CTIS2023-503703-28-00
- Lead Sponsor
- Berlin-Chemie AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method